Amgen Q3 revenue beats expectations on higher volumes

What happened

Amgen reported that third-quarter revenue rose 8% and adjusted earnings per share increased 14%, with both results beating analyst expectations. The company said higher product sales volumes drove growth, while global biosimilar launches contributed to declines in Prolia and XGEVA sales.

Confirmed

Global impact / market context

Higher sales volumes supported revenue and adjusted earnings growth, but the declines in Prolia and XGEVA show that competition from biosimilar drugs can reduce sales of established products. Higher operating expenses also partly offset earnings growth, so stronger revenue does not automatically mean costs are contained.

Analyst inference

The supplied context says analysts rated Amgen shares “hold” on average, while the broader pharmaceutical peer group averaged “buy.” That contrast suggests the company’s results are weighed alongside product-level competition and costs, not just its quarterly beats; the article gives no post-results share-price reaction.

Analyst inference

What to watch

1. Whether higher sales volumes continue to support product revenue, since Amgen identified volume growth as the driver of third-quarter sales growth. Analyst inference
2. How Prolia and XGEVA sales change as biosimilar versions launch globally; continued declines could weigh on Amgen’s product revenue. Analyst inference
3. Whether operating costs keep offsetting earnings growth, and whether planned capital spending supports future operations without weakening cash available. Analyst inference

Evidence

• Original source link unavailable